Plasmodium falciparum is one of the two protozoan parasites responsible for most of the world's cases of human malaria (the other being P. vivax). Hay et al. (2010) estimated that in 2010 there were around 450 million clinical cases of P. falciparum malaria in the world. Based on where they live, an estimated 2.5 billion people were at possible risk of infection with P. falciparum as of 2005. Three quarters of people exposed to P. falciparum risk live in just ten countries. (Guerra et al. 2006). According to Hay et al. (2010), around half the world’s estimated P. falciparum clinical cases (and nearly half the statistical uncertainty in estimates) derive from just four countries: India, Nigeria, Democratic Republic of the Congo (DRC), and Myanmar (Burma). 60% of the estimated world falciparum malaria burden falls in Africa and nearly a quarter on Nigeria and DRC alone. The current falciparum malaria burden in India is very unclear, but official surveillance numbers appear to be dramatic understimates. India's malaria problem is probably exacerbated by the unique problem of urban malaria, maintained by Anopheles stephensi. (Hay et al. 2010) Plasmodium falciparum is responsible for most of the nearly one million people (many of them children) killed by malaria each year.
The human malaria parasite life cycle involves two hosts, a mosquito and a human. The life cycle is very complex, including both sexual and asexual phases (see life cycle diagram) and involves a stage in the liver as well as the blood stage, the latter being responsible for the clinical manifestations of the disease. (Centers for Disease Control Parasites and Health website)
- joint pain
- severe brain damage
- cognitive impairments - especially in children
- enlarged liver and/or spleen
- severe headache
- cerebral ischemia (lack of adequate blood flow)
- low blood sugar
- renal failure
- death - young children and pregnant women are especially vulnerable
- better understand disease distribution in rural villages better
- promote the distribution of bed-nets and treatment availability
- understand the relationship between malaria and other tropical diseases
- during a blood meal, a malaria-infected female Anopheles mosquito injects P. falciparum parasites into the human host
- the parasites travel via the blood to the liver, where they infect liver cells
- they mature and move back to the blood where they undergo asexual multiplication inside the human red blood cells (ring-stage)
- in the blood, some parasites can differentiate into sexual stages (gametocytes)
- blood stage parasites are responsible for the symptoms of the disease
- the gametocytes, male and female, are ingested by an Anopheles mosquito during a blood meal
- while in the mosquito's stomach, the male parasite penetrates the female parasite and this new parasite form becomes motile, able to invade the midgut wall of the mosquito where it develops into oocysts (or eggs)
- they grow, rupture, and release further parasites in a new form capable of moving towards the mosquito's salivary glands ready for inoculation into a new human host to perpetuate the malaria life cycle
The most obvious features that distinguish Plasmodium vivax from P. falciparum include the development of dormant forms in the liver known as "hypnozoites", which cause subsequent infections in the blood called relapses; the appearance (sometimes before onset of clinical symptoms) of round gametocytes in the peripheral blood (i.e., not banana-shaped gametocytes like those produced by P. falciparum); a predilection (or requirement) of merozoites for reticulocytes as host cells; circulation of all blood-stage developmental forms in the peripheral blood; the absence of electron-dense protrusions (known as knobs in P. falciparum); and the presence of numerous caveolae–vesicle complexes along the surface of infected red blood cells. (Mueller et al. 2009 and references therein)
Diseases and Parasites
P. falciparum can be identified using several methods which are used to diagnose malaria disease.
Microscopic examination of blood films
The most economic, preferred and reliable diagnostic method for malaria is microscopic examination of blood films. Thin or thick films stained with Giemsa allow a skilled microscope technician to identify parasites and have an idea of infection intensity - or parasitaemia.New microscopy methods are being developed, with different staining techniques, for example a portable fluorescent microscope allows for a quicker but less reliable diagnosis. Fluorescence is incredibly useful for rapid identification of parasites, featured as bright green fluorescence in a black background.
For faster diagnosis when microscopy is not available or laboratory staff are not experienced, there are now commercial antigen detection tests that require only a drop of blood. Malaria rapid diagnostic tests (RDTs) take 15–20 minutes to make a diagnosis. Unlike microscopy-based diagnosis, RDTs tend to be more expensive and harder to make available in rural areas.
Molecular methods are available in some clinical laboratories. Based on the polymerase chain reaction (PCR), they are more accurate than microscopy. However, these methods are expensive and require a specialised laboratory.
Active malaria infection with P. falciparum requires hospitalisation so pathology can be minimised and parasitaemia contained using specific antimalarial drugs.
P. falciparum is able to develop resistance to most anti-malarial drugs, and for this reason the World Health Organisation now recommends the use of two or more drugs simultaneously. The latest most effective drugs are artemisinin combination therapies (ACTs). The primary compound - artemisinin - is combined with several others, such as mefloquine (ASMQ), lumefantrine (Coartem), amodiaquine (ASAQ), piperaquine (Duo-Cotecxin) and antifolates (Ariplus).
Evolution and Systematics
Systematics and Taxonomy
There are more than 150 named species of Plasmodium that infect various species of vertebrates. Four species are well known as true parasites of humans, utilizing humans almost exclusively as a natural intermediate host: P. falciparum, P. vivax, P. ovale and P. malariae. In recent years it has become apparent that the simian malaria parasite P. knowlesi also regularly infects humans, as well as its natural monkey intermediate hosts. (Centers for Disease Control Parasites and Health website) Furthermore, it is now apparent that there are likely two distinct Plasmodium species that have both been referred to as P. ovale (Sutherland et al. 2010; Oguike et al. 2011).
Plasmodium falciparum is a protozoan parasite, one of the species of Plasmodium that cause malaria in humans. It is transmitted by the female Anopheles mosquito. Malaria caused by this species (also called malignant or falciparum malaria) is the most dangerous form of malaria, with the highest rates of complications and mortality. As of 2006, there were an estimated 247 million human malarial infections (98% in Africa, 70% being 5 years or younger). It is much more prevalent in sub-Saharan Africa than in many other regions of the world; in most African countries, over 75% of cases were due to P. falciparum, whereas in most other countries with malaria transmission, other, less virulent plasmodial species predominate. Almost every malarial death is caused by P. falciparum.
- 1 Background
- 2 Plasmodium life cycle
- 3 Pathogenesis
- 4 Microscopic appearance
- 5 The Plasmodium falciparum genome
- 6 Influence of P. falciparum on the human genome
- 7 Known vectors
- 8 Origins and Evolution
- 9 Treatment
- 10 Vaccination
- 11 See also
- 12 References
- 13 Sources and further reading
Malaria is caused by an infection with protozoa of the genus Plasmodium. The name malaria, from the Italian mala aria, meaning "bad air", comes from the linkage suggested by Giovanni Maria Lancisi (1717) of malaria with the poisonous vapours of swamps. This species name comes from the Latin falx, meaning "sickle", and parere meaning "to give birth". The organism itself was first seen by Laveran on November 6, 1880 at a military hospital in Constantine, Algeria, when he discovered a microgametocyte exflagellating. Patrick Manson (1894) hypothesised that mosquitoes could transmit malaria. This hypothesis was experimentally confirmed independently by Giovanni Battista Grassi and Ronald Ross in 1898. Grassi (1900) proposed an exerythrocytic stage in the life cycle, later confirmed by Short, Garnham, Covell and Shute (1948), who found Plasmodium vivax in the human liver.
Around the world, malaria is the most significant parasitic disease of humans, and claims the lives of more children worldwide than any other infectious disease. Since 1900, the area of the world exposed to malaria has been halved, yet two billion more people are presently exposed. Morbidity, as well as mortality, is substantial. Infection rates in children in endemic areas are of the order of 50%: Chronic infection has been shown to reduce school scores by up to 15%. Reduction in the incidence of malaria coincides with increased economic output.
While there are no effective vaccines for any of the six or more species that cause human malaria, drugs have been employed for centuries. In 1640, Huan del Vego first employed the tincture of the cinchona bark for treating malaria; the native Indians of Peru and Ecuador had been using it even earlier for treating fevers. Thompson (1650) introduced this "Jesuits' bark" to England. Its first recorded use there was by Dr John Metford of Northampton in 1656. Morton (1696) presented the first detailed description of the clinical picture of malaria and of its treatment with cinchona. Gize (1816) studied the extraction of crystalline quinine from the cinchona bark, and Pelletier and Caventou (1820) in France extracted pure quinine alkaloids, which they named quinine and cinchonine.
Plasmodium life cycle
The life cycle of all Plasmodium species is complex. Infection in humans begins with the bite of an infected female Anopheles mosquito. Sporozoites released from the salivary glands of the mosquito enter the bloodstream during feeding, quickly invading liver cells (hepatocytes). Sporozoites are cleared from the circulation within 30 minutes. During the next 14 days in the case of P. falciparum, the liver-stage parasites differentiate and undergo asexual multiplication, resulting in tens of thousands of merozoites that burst from the hepatocyte. Individual merozoites invade red blood cells (erythrocytes) and undergo an additional round of multiplication, producing 12-16 merozoites within a schizont. The length of this erythrocytic stage of the parasite lifecycle depends on the parasite species: irregular cycle for P. falciparum, 48 hours for P. vivax and P. ovale, and 72 hours for P. malariae. The clinical manifestations of malaria, fever, and chills are associated with the synchronous rupture of the infected erythrocytes. The released merozoites go on to invade additional erythrocytes. Not all of the merozoites divide into schizonts; some differentiate into sexual forms, male and female gametocytes. These gametocytes are taken up by a female Anopheles mosquito during a blood meal. Within the mosquito midgut, the male gametocyte undergoes a rapid nuclear division, producing eight flagellated microgametes that fertilize the female macrogamete. The resulting ookinete traverses the mosquito gut wall and encysts on the exterior of the gut wall as an oocyst. Soon, the oocyst ruptures, releasing hundreds of sporozoites into the mosquito body cavity, where they eventually migrate to the mosquito salivary glands.
Plasmodium falciparum causes severe malaria via a distinctive property not shared by any other human malaria, that of sequestration. Within the 48-hour asexual blood stage cycle, the mature forms change the surface properties of infected red blood cells, causing them to stick to blood vessels (a process called cytoadherence). This leads to obstruction of the microcirculation and results in dysfunction of multiple organs, typically the brain in cerebral malaria.
Among medical professionals, the preferred method to diagnose malaria and determine which species of Plasmodium is causing the infection is by examination of a blood film under microscope in a laboratory. Each species has distinctive physical characteristics that are apparent under a microscope. In P. falciparum, only early (ring-form) trophozoites and gametocytes are seen in the peripheral blood. It is unusual to see mature trophozoites or schizonts in peripheral blood smears, as these are usually sequestered in the tissues. The parasitised erythrocytes are not enlarged, and it is common to see cells with more than one parasite within them (multiply parasitised erythrocytes). On occasion, faint, comma-shaped, red dots called "Maurer's dots" are seen on the red cell surface. The comma-shaped dots can also appear as pear-shaped blotches.
The Plasmodium falciparum genome
In 1995, a consortium, the malaria genome project (MGP), was set up to sequence the genome of P. falciparum. The genome of its mitochondrion was reported in 1995, that of the nonphotosynthetic plastid known as the apicoplast in 1996, and the sequence of the first nuclear chromosome (chromosome 2) in 1998. The sequence of chromosome 3 was reported in 1999, and the entire genome on 3 October 2002. Annotated genome data can now be fully analyzed at several database resources including the UCSC Malaria Genome Browser, PlasmoDB and GeneDB. The ~24 megabase genome is extremely AT-rich (~80%) and is organised into 14 chromosomes: Just over 5,300 genes were described.
Influence of P. falciparum on the human genome
The presence of the parasite in human populations caused selection in the human genome in a multitude of ways, as humans have been forced to develop resistance to the disease. Beet, a doctor working in Southern Rhodesia (now Zimbabwe) in 1948, first suggested that sickle-cell disease could offer some protection to malaria. This suggestion was reiterated by J. B. S. Haldane in 1949, who suggested that thalassaemia could provide similar protection. This hypothesis has since been confirmed and has been extended to hemoglobin C and hemoglobin E, abnormalities in ankyrin and spectrin (ovalocytosis, elliptocytosis), in glucose-6-phosphate dehydrogenase deficiency and pyruvate kinase deficiency, loss of the Gerbich antigen (glycophorin C) and the Duffy antigen on the erythrocytes, thalassemias and variations in the major histocompatibility complex classes 1 and 2 and CD32 and CD36.
P. falciparum and sickle cell anemia
Individuals with sickle-cell anemia or sickle-cell trait do have reduced parasitemia when compared to wild-type individuals for the hemoglobin protein in red blood cells. Studies have shown these genetic deviations of hemoglobin from normal states provide protection against the deadly parasite that causes malaria (Allison, 1954).
Of the six malarial parasites, P. falciparum causes the most fatal and medically severe form. Malaria is prevalent in tropical countries with an incidence of 300 million per year and a mortality rate of 1 to 2 million per year. Roughly 50% of all malarial infections are caused by P. falciparum (Roberts and Janovy Jr., 2005). Upon infection via a bite from an infected Anopheles mosquito, sporozoites devastate the human body by first infecting the liver. While in the liver, sporozoites undergo asexual development and merozoites are released into the bloodstream. The trophozoites further develop and reproduce by invading red blood cells. During the reproduction cycle, Plasmodium falciparum produces up to 40,000 merozoites in one day. Other blood sporozoans, such as Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae, that infect humans and cause malaria do not have such a productive cycle for invasion. The process of bursting red blood cells does not have any symptoms, however destruction of the cells does cause anemia, since the bone marrow cannot compensate for the damage. When red blood cells rupture, hemozoin wastes cause cytokine release, chills, and then fever (Roberts and Janovy Jr., 2005).
Plasmodium falciparum trophozoites develop sticky knobs in red blood cells, which then adhere to endothelial cells in blood vessels, thus evading clearance in the spleen. The acquired adhesive nature of the red blood cells may cause cerebral malaria when sequestered cells prevent oxygenation of the brain. Symptoms of cerebral malaria include impaired consciousness, convulsions, neurological disorder, and coma (Brown University). Additional complications from Plasmodium falciparum induced malaria include advanced immunosuppression (Roberts and Janovy Jr., 2005).
Individuals with sickle-cell trait and sickle-cell anemia are privileged because they have altered sticky knobs. Research by Cholera, R., Brittain, N., Gillrie, M. et al. (2007) has shown that parasitemia (the ability of a parasite to infect) because merozoites of each parasite species that cause malaria invade the red blood cell in three stages: contact, attachment, and endocytosis. Individuals suffering from sickle-cell anemia have deformed red blood cells that interfere with the attachment phase, and Plasmodium falciparum and the other forms of malaria have trouble with endocytosis.
These individuals have reduced attachment when compared to red blood cells with the normally functioning hemoglobin because of differing protein interactions. In normal circumstances, merozoites enter red blood cells through two PfEMP-1 protein-dependent interactions. These interactions promote the malaria inflammatory response associated with symptoms of chills and fever. When these proteins are impaired, as in sickle-cell cases, parasites cannot undergo cytoadherance interactions and cannot infect the cells; therefore, sickle-cell-anemic individuals and individuals carrying the sickle-cell trait have lower parasite loads and shorter time for symptoms than individuals expressing normal red blood cells (Mockenhaupt, 2004).
Individuals with sickle-cell anemia may also experience greatly reduced symptoms of malaria because Plasmodium falciparum trophozoites cannot bind to hemoglobin in order to form sticky knobs. Without knob-binding complexes, which is an exclusive feature of Plasmodium falciparum, red blood cells do not stick to endothelial walls of blood vessels, and infected individuals do not experience symptoms such as cerebral malaria (Cholera, R., Brittain, N., Gillrie, M. et al. 2007).
Many may wonder why natural selection has not phased out sickle-cell anemia. The answer lies within answers generated by Cholera, R., Brittain, N., Gillrie, M. et al. (2007). Individuals with sickle-cell trait are greatly desired in areas where malarial infections are endemic. Malaria kills between 1 and 2 million people per year. It is the leading cause of death among children in tropical regions. Individuals with sickle-cell deformities are able to fight Plasmodium parasite infections and do not become victims of malarial demise. Therefore, individuals expressing the genes and individuals carrying genes are selected to remain within the population (Allison 1964). It is no surprise that the incidence of sickle-cell anemia matches that of endemic regions for malarial infections.
- Anopheles gambiae (Principal vector)
- Anopheles albimanus
- Anopheles freeborni
- Anopheles maculatus
- Anopheles stephensi
Origins and Evolution
The closest relative of Plasmodium falciparum is Plasmodium reichenowi, a parasite of chimpanzees. P. falciparum and P. reichenowi are not closely related to the other Plasmodium species that parasitize humans, or indeed mammals in general. It has been argued that these two species originated from a parasite of birds. More recent analyses do not support this, however, instead suggesting that the ability to parasitize mammals evolved only once within the genus Plasmodium.
New evidence based on analysis of more than 1,100 mitochondrial, apicoplastic, and nuclear DNA sequences has suggested that Plasmodium falciparum may in fact have speciated from a lineage present in gorillas.
According to this theory, P. falciparum and P. reichenowi may both represent host switches from an ancestral line that infected primarily gorillas; P. falciparum went on to infect primarily humans, while P. reichenowi specialized in chimpanzees. The ongoing debate over the evolutionary origin of Plasmodium falciparum will likely be the focus of continuing genetic study.
A third species that appears to related to these two has been discovered: Plasmodium gaboni. This putative species is currently (2009) known only from two DNA sequences and awaits a full species description before it can be regarded as valid.
Molecular clock analyses suggest that P. falciparum is as old as the human line; the two species diverged at the same time as humans and chimpanzees. However, low levels of polymorphism within the P. falciparum genome suggest a much more recent origin. It may be that this discrepancy exists because P. falciparum is old, but its population recently underwent a great expansion. Some evidence still indicates that P. reichenowi was the ancestor of P. falciparum. The timing of this event is unclear at present but it has been proposed that it may have occurred about 10,000 years ago.
More recently, P. falciparum has evolved in response to human interventions. Most strains of malaria can be treated with chloroquine, but P. falciparum has developed resistance to this treatment. A combination of quinine and tetracycline has also been used, but there are strains of P. falciparum that have grown resistant to this treatment as well. Different strains of P. falciparum have grown resistant to different treatments. Often, the resistance of the strain depends on where it was contracted. Many cases of malaria that come from parts of the Caribbean and west of the Panama Canal as well as the Middle East and Egypt can often be treated with chloroquine, since they have not yet developed resistance. Nearly all cases contracted in Africa, India, and southeast Asia have grown resistant to this medication, and there have been cases in Thailand and Cambodia in which the strain has been resistant to nearly all treatments. Often the strain grows resistant to the treatment in areas where the use is not as tightly regulated.
Like most apicomplexans, malaria parasites harbor a plastid, an apicoplast, similar to plant chloroplasts, which they probably acquired by engulfing (or being invaded by) a eukaryotic alga, and retaining the algal plastid as a distinctive organelle encased within four membranes - (see endosymbiotic theory). The apicoplast, is an essential organelle, thought to be involved in the synthesis of lipids and several other compounds, and it provides an attractive target for antimalarial drug development, in particular in light of the emergence of parasites resistant to chloroquine and other existing antimalarial agents.
Uncomplicated falciparum malaria
According to WHO guidelines 2010, artemisinin-based combination therapies (ACTs) are the recommended first line antimalarial treatments for uncomplicated malaria caused by P. falciparum. The following ACTs are recommended by the WHO:
- artemether plus lumefantrine
- artesunate plus amodiaquine
- artesunate plus mefloquine
- artesunate plus sulfadoxine-pyrimethamine
- dihydroartemisinin plus piperaquine
The choice of ACT in a country or region will be based on the level of resistance to the constituents in the combination. Artemisinin and its derivatives should not be used as monotherapy in uncomplicated falciparum malaria. As second-line antimalarial treatment, when initial treatment doesn’t work or stops working, it is recommended to use an alternative ACT known to be effective in the region, such as:
- Artesunate plus tetracycline or doxycycline or clindamycin.
- Quinine plus tetracycline or doxycycline or clindamycin
Any of these combinations are to be given for 7 days.
A Cochrane systematic review published in 2014, provided evidence that in Africa the overall treatment failure was lesser for dihydroartemisinin-piperaquine when compared to artemether-lumefantrine and both drugs had PCR adjusted failure rates of less than 5%.However in Asian countries, dihydroartemisinin-piperaquine was found to be better tolerated but as effective as artesunate plus mefloquine. 
For pregnant women, the recommended first-line treatment during the first trimester is quinine plus clindamycin for 7 days. Artesunate plus clindamycin for 7 days is indicated if this treatment fails. Still, an ACT is indicated only if this is the only treatment immediately available, or if treatment with 7-day quinine plus clindamycin fails or if there is uncertainty of compliance with a 7-day treatment. In second and third trimesters, the recommended treatment is an ACT known to be effective in the country/region or artesunate plus clindamycin for 7 days, or quinine plus clindamycin for 7 days. Lactating women should receive standard antimalarial treatment (including ACTs) except for dapsone, primaquine and tetracyclines.
In infants and young children, the recommended first-line treatment is ACTs, with attention to accurate dosing and ensuring the administered dose is retained.
For travellers returning to non-endemic countries, any of the following is recommended:
Severe falciparum malaria
In severe falciparum malaria, it is recommended that rapid clinical assessment and confirmation of the diagnosis be made, followed by administration of full doses of parenteral antimalarial treatment without delay with whichever effective antimalarial is first available.
For children, especially in the malaria-endemic areas of Africa, any the following antimalarial medicines is recommended:
- artesunate IV or IM
- quinine (IV infusion or divided IM injection)
- artemether IM. It should be used only if none of the alternatives are available, as its absorption may be erratic.
Parenteral antimalarials should be administered for a minimum of 24 hours in the treatment of severe malaria, irrespective of the patient's ability to tolerate oral medication earlier. Thereafter, it is recommended to complete treatment by giving a complete course of any of the following:
- an ACT
- artesunate plus clindamycin or doxycycline
- quinine plus clindamycin or doxycycline
If complete treatment of severe malaria is not possible, it is recommended that patients be given pre-referral treatment and referred immediately to an appropriate facility for further treatment. The following are options for pre-referral treatment:
- rectal artesunate
- quinine IM
- artesunate IM
- artemether IM
History of falciparum treatment
Attempts to make synthetic antimalarials began in 1891. Atabrine, developed in 1933, was used widely throughout the Pacific in World War II but was deeply unpopular because of the yellowing of the skin it caused. In the late 1930s, the Germans developed chloroquine, which went into use in the North African campaigns. Mao Zedong encouraged Chinese scientists to find new antimalarials after seeing the casualties in the Vietnam War. Artemisinin was discovered in the 1970s based on a medicine described in China in the year 340. This new drug became known to Western scientists in the late 1980s and early 1990s and is now a standard treatment. In 1976, P. falciparum was successfully cultured in vitro for the first time, which facilitated the development of new drugs substantially. A 2008 study published in the New England Journal of Medicine highlighted the emergence of artemisinin-resistant strains of P.falciparum in Cambodia.
Although an antimalarial vaccine is urgently needed, infected individuals never develop a sterilizing (complete) immunity, making the prospects for such a vaccine dim. The parasites live inside cells, where they are largely hidden from the immune response. Infection has a profound effect on the immune system including immune suppression. Dendritic cells suffer a maturation defect following interaction with infected erythrocytes and become unable to induce protective liver-stage immunity. Infected erythrocytes directly adhere to and activate peripheral blood B cells from nonimmune donors. The var gene products, a group of highly expressed surface antigens, bind the Fab and Fc fragments of human immunoglobulins in a fashion similar to protein A to Staphylococcus aureus, which may offer some protection to the parasite from the human immune system. Despite the poor prospects for a fully protective vaccine, it may be possible to develop a vaccine that would reduce the severity of malaria for children living in endemic areas.
- Rich, S. M.; Leendertz, F. H.; Xu, G.; Lebreton, M.; Djoko, C. F.; Aminake, M. N.; Takang, E. E.; Diffo, J. L. D.; Pike, B. L.; Rosenthal, B. M.; Formenty, P.; Boesch, C.; Ayala, F. J.; Wolfe, N. D. (2009). "The origin of malignant malaria". Proceedings of the National Academy of Sciences 106 (35): 14902–14907. doi:10.1073/pnas.0907740106. PMC 2720412. PMID 19666593.
- Perkins, D. J.; Were, T.; Davenport, G. C.; Kempaiah, P.; Hittner, J. B.; Ong'Echa, J. M. (2011). "Severe malarial anemia: Innate immunity and pathogenesis". International journal of biological sciences 7 (9): 1427–1442. doi:10.7150/ijbs.7.1427. PMC 3221949. PMID 22110393.
- Perlmann, P; Troye-Blomberg, M (2000). "Malaria blood-stage infection and its control by the immune system". Folia biologica 46 (6): 210–8. PMID 11140853.
- "World Malaria Report 2008". World Health Organisation. 2008. p. 10. Retrieved 2009-08-17.
- Biodiversity of the Malaria in the World, Sylvie Manguin et al. Editorial John Libbey, 2008. p. 23
- Dondorp AM, Pongponratn E, White NJ (February 2004). "Reduced microcirculatory flow in severe falciparum malaria: pathophysiology and electron-microscopic pathology". Acta Trop. 89 (3): 309–17. doi:10.1016/j.actatropica.2003.10.004. PMID 14744557.
- Wilson RJ; Denny PW; Preiser PR et al. (August 1996). "Complete gene map of the plastid-like DNA of the malaria parasite Plasmodium falciparum". Journal of Molecular Biology 261 (2): 155–72. doi:10.1006/jmbi.1996.0449. PMID 8757284.
- Gardner MJ; Hall N; Fung E; and others; Berriman, Matthew; Hyman, Richard W.; Carlton, Jane M.; Pain, Arnab; Nelson, Karen E.; Bowman, Sharen; Paulsen, Ian T.; James, Keith; Eisen, Jonathan A.; Rutherford, Kim; Salzberg, Steven L.; Craig, Alister; Kyes, Sue; Chan, Man-Suen; Nene, Vishvanath; Shallom, Shamira J.; Suh, Bernard; Peterson, Jeremy; Angiuoli, Sam; Pertea, Mihaela; Allen, Jonathan; Selengut, Jeremy; Haft, Daniel; Mather, Michael W.; Vaidya, Akhil B. et al. (October 2002). "Genome sequence of the human malaria parasite Plasmodium falciparum". Nature 419 (6906): 498–511. Bibcode:2002Natur.419..498G. doi:10.1038/nature01097. PMID 12368864.
- Mbogo CM; Mwangangi JM; Nzovu J et al. (June 2003). "Spatial and temporal heterogeneity of Anopheles mosquitoes and Plasmodium falciparum transmission along the Kenyan coast". Am. J. Trop. Med. Hyg. 68 (6): 734–42. PMID 12887036.
- Rathore, D; Wahl AM, Sullivan M, McCutchan TF (2001-04-25). "A phylogenetic comparison of gene trees constructed from plastid, mitochondrial and genomic DNA of Plasmodium species". Molecular and Biochemical Parasitology 114 (1): 89–94. doi:10.1016/S0166-6851(01)00241-9. PMID 11356517.
- Yotoko, KSC; C Elisei (November 2006). "Malaria parasites (Apicomplexa, Haematozoea) and their relationships with their hosts: is there an evolutionary cost for the specialization?". Journal of Zoological Systematics and Evolutionary Research 44 (4): 265–73. doi:10.1111/j.1439-0469.2006.00377.x.
- Liu, W; Y Li, GH Learn, RS Rudicell, JD Robertson, BF Keele, JN Ndjango, CM Sanz, DB Morgan, S Locatelli, MK Gonder, PJ Kranzusch, PD Walsh, E Delaporte, E Mpoudi-Ngole, AV Georgiev, MN Muller, GM Shaw, M Peeters, PM Sharp, JC Rayner, BH Hahn (2010). "Origin of the human malaria parasite Plasmodium falciparum in gorillas". Nature 467 (7314): 420–5. Bibcode:2010Natur.467..420L. doi:10.1038/nature09442. PMC 2997044. PMID 20864995.
- Duval, L; M Fourment, E Nerrienet, D Rousset, SA Sadeuh, SM Goodman, NV Andriaholinirina, M Randrianarivelojosia, RE Paul, V Robert, FJ Ayala, F Ariey (2010). "African apes as reservoirs of Plasmodium falciparum and the origin and diversification of the Laverania subgenus". Proceedings of the National Academy of Sciences of the United States of America 107 (23): 10561–6. Bibcode:2010PNAS..10710561D. doi:10.1073/pnas.1005435107. PMC 2890828. PMID 20498054.
- Rayner, J; WM Liu, M Peeters, PM Sharp, BH Hahn (2011). "A plethora of Plasmodium species in wild apes: a source of human infection?". Trends in Parasitology 467 (5): 222. doi:10.1016/J.Pt.2011.01.006.
- Prugnolle, F; P Durand, B Ollomo, L Duval, F Ariey, C Arnathau, JP Gonzalez, E Leroy, F Renaud (2011). "A Fresh Look at the Origin of Plasmodium falciparum, the Most Malignant Malaria Agent". In Manchester, Marianne. PLOS Pathogens 7 (2): e1001283. doi:10.1371/journal.ppat.1001283. PMC 3044689. PMID 21383971.
- Escalante, AA; E Barrio, FJ Ayala (1995). "Evolutionary origin of human and primate malarias: evidence from the circumsporozoite protein gene". Molecular Biology and Evolution 12 (4): 616–26. ISSN 0737-4038. PMID 7659017.
- Hartl, DH (January 2004). "The origin of malaria: mixed messages from genetic diversity". Nature Reviews Microbiology 2 (1): 15–22. doi:10.1038/nrmicro795. PMID 15035005.
- Joy, DA; Feng X, Mu J, Furuya T, Chotivanich K, Krettli AU, Ho M, Wang A, White NJ, Suh E, Beerli P, Su XZ. (2003-04-11). "Early origin and recent expansion of Plasmodium falciparum". Science 300 (5617): 318–21. Bibcode:2003Sci...300..318J. doi:10.1126/science.1081449. PMID 12690197.
- Rich SM, Leendertz FH, Xu G, Lebreton M, Djoko CF, Aminake MN, Takang EE, Diffo JL, Pike BL, Rosenthal BM, Formenty P, Boesch C, Ayala FJ, Wolfe ND; Leendertz; Xu; Lebreton; Djoko; Aminake; Takang; Diffo; Pike; Rosenthal; Formenty; Boesch; Ayala; Wolfe (2009). "The origin of malignant malaria". Proc Natl Acad Sci USA 106 (35): 14902–7. Bibcode:2009PNAS..10614902R. doi:10.1073/pnas.0907740106. PMC 2720412. PMID 19666593.
- Guidelines for the treatment of malaria, second edition Authors: WHO. Number of pages: 194. Publication date: 2010. Languages: English. ISBN 978-92-4-154792-5
- Babalwa Zani et al. (2014). "Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria". Cochrane Database of Systematic Reviews 1. doi:10.1002/14651858.CD010927.
- Trager, W; J B Jensen (1976-08-20). "Human malaria parasites in continuous culture". Science 193 (4254): 673–5. Bibcode:1976Sci...193..673T. doi:10.1126/science.781840. PMID 781840.
- Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM (December 2008). "Evidence of artemisinin-resistant malaria in western Cambodia". N. Engl. J. Med. 359 (24): 2619–20. doi:10.1056/NEJMc0805011. PMID 19064625.
Sources and further reading
Pathology due to Plasmodium falciparum
- Gross pathology
- Low power H & E stain
- High power H & E stain showing parasite adherence to the vessel walls
Plasmodium falciparum genome data
- Gardner, MJ; Hall, N; Fung, E; White, O; Berriman, M; Hyman, RW; Carlton, JM; Pain, A; Nelson, KE (2002). "Genome sequence of the human malaria parasite Plasmodium falciparum". Nature 419 (6906): 498–511. Bibcode:2002Natur.419..498G. doi:10.1038/nature01097. PMID 12368864.
- PlasmoDB: The Plasmodium Genome Resource
- GeneDB Plasmodium falciparum
- UCSC Plasmodium Falciparum Browser
- Colombian scientists develop computacional tool to detect the plasmodium falciparum (in spanish)
- Allison AC (February 1954). "Protection Afforded by Sickle-cell Trait Against Subtertian Malarial Infection". Br Med J 1 (4857): 290–4. doi:10.1136/bmj.1.4857.290. PMC 2093356. PMID 13115700.
- Allison AC (1964). "Polymorphism and Natural Selection in Human Populations". Cold Spring Harb. Symp. Quant. Biol. 29: 137–49. PMID 14278460.
- Cholera R; Brittain NJ; Gillrie MR et al. (January 2008). "Impaired cytoadherence of Plasmodium falciparum-infected erythrocytes containing sickle hemoglobin". Proc. Natl. Acad. Sci. U.S.A. 105 (3): 991–6. Bibcode:2008PNAS..105..991C. doi:10.1073/pnas.0711401105. PMC 2242681. PMID 18192399.
- Mockenhaupt FP; Ehrhardt S; Otchwemah R et al. (May 2004). "Limited influence of haemoglobin variants on Plasmodium falciparum msp1 and msp2 alleles in symptomatic malaria". Trans. R. Soc. Trop. Med. Hyg. 98 (5): 302–10. doi:10.1016/j.trstmh.2003.10.001. PMID 15109555.
- Janovy, John; Roberts, Larry S. (2005). Foundations of Parasitology (7th ed.). McGraw-Hill Education (ISE Editions). ISBN 0-07-111271-5.
Plasmodium falciparum biology
Plasmodium falciparum has been the focus of much research due to it being the causative agent of malaria. This article describes some of the recent findings surrounding the unique biology of this organism.
- 1 Life Cycle
- 2 Cell Biology
- 3 Genome
- 4 Transcriptome
- 5 Proteome
- 6 Metabolism
- 7 Human immune system evasion
- 8 Research
- 9 References
- 10 Additional material
- 11 External links
P. falciparum is transmitted to humans by the females of the Anopheles species of mosquito. There are about 460 species of Anopheles mosquito, but only 68 transmit malaria. Anopheles gambiae is one of the best malaria vectors since it is long-lived, prefers feeding on humans, and lives in areas near human habitation. A. gambiae is found in Africa.
Prior to transmission, Plasmodium falciparum resides within the salivary gland of the mosquito. The parasite is in its sporozoite stage at this point. As the mosquito takes its blood meal, it injects a small amount of saliva into the skin wound. The saliva contains antihemostatic and anti-inflammatory enzymes that disrupt the clotting process and inhibit the pain reaction. Typically, each infected bite contains 5-200 sporozoites which proceed to infect the human vector. Once in the human bloodstream, the sporozoites only circulate for a matter of minutes before infecting liver cells.
After circulating in the bloodstream, the P. falciparum sporozoites enter hepatocytes. At this point, the parasite loses its apical complex and surface coat, and transforms into a trophozoite. Within the parasitophorous vacuole of the hepatocyte, P. falciparum undergoes schizogonic development. In this stage, nucleus divides multiple times with a concomitant increase in cell size, but without cell segmentation. This exoerythrocytic schizogony stage of P. falciparum has a minimum duration of roughly 5.5 days. After segmentation, the parasite cells are differentiated into merozoites.
After release from the hepatocytes, the merozoites enter the bloodstream prior to infecting red blood cells. At this point, the merozoites are roughly 1.5 μm in length and 1 μm in diameter, and use the apicomplexan invasion organelles (apical complex, pellicle and surface coat) to recognize and enter the host erythrocyte.
The parasite first binds to the erythrocyte in a random orientation. It then reorients such that the apical complex is in proximity to the erythrocyte membrane. A tight junction is formed between the parasite and erythrocyte. As it enters the red blood cell, the parasite forms a parasitophorous vesicle, to allow for its development inside the erythrocyte.
After invading the erythrocyte, the parasite loses its specific invasion organelles (apical complex and surface coat) and de-differentiates into a round trophozoite located within a parasitophorous vacuole in the red blood cell cytoplasm. The young trophozoite (or "ring" stage, because of its morphology on stained blood films) grows substantially before undergoing schizogonic division.
At the schizont stage, the parasite replicates its DNA multiple times without cellular segmentation. These schizonts then undergo cellular segmentation and differentiation to form roughly 16-18 merozoite cells in the erythrocyte. The merozoites burst from the red blood cell, and proceed to infect other erythrocytes. The parasite is in the bloodstream for roughly 60 seconds before it has entered another erythrocyte.
This infection cycle occurs in a highly synchronous fashion, with roughly all of the parasites throughout the blood in the same stage of development. This precise clocking mechanism has been shown to be dependent on the human host's own circadian rhythm. Specifically, human body temperature changes, as a result of the circadian rhythm, seem to play a role in the development of P. falciparum within the erythrocytic stage.
Within the red blood cell, the parasite metabolism depends greatly on the digestion of hemoglobin.
Infected erythrocytes are often sequestered in various human tissues or organs, such as the heart, liver and brain. This is caused by parasite-derived cell surface proteins being present on the red blood cell membrane, and it is these proteins that bind to receptors on human cells. Sequestration in the brain causes cerebral malaria, a very severe form of the disease, which increases the victim's likelihood of death.
The parasite can also alter the morphology of the red blood cell, causing knobs on the erythrocyte membrane.
During the erythrocytic stage, some merozoites develop into male and female gametocytes. This process is called gametocytogenesis. The specific factors and causes underlying this sexual differentiation are largely unknown. These gametocytes take roughly 8–10 days to reach full maturity. Note that the gametocytes remain within the erythrocytes until taken up by the mosquito host.
Upon being taken up by the mosquito, the gametocytes leave the erythrocyte shell and differentiate into gametes. The female gamete maturation process entails slight morphological changes, as it becomes enlarged and spherical. On the other hand, the male gamete maturation involves significant morphological development. The male gamete's DNA divides three times to form eight nuclei. Concurrently, eight flagella are formed. Each flagella pairs with a nucleus to form a microgamete, which separates from the parasite cell. This process is referred to as exflagellation.
Fertilization of the female gamete by the male gamete occurs rapidly after gametogenesis. The fertilization event produces a zygote. The zygote then develops into an ookinete. The zygote and ookinete are the only diploid stages of P. falciparum.
The diploid ookinete is an invasive form of P. falciparum within the mosquito. It traverses the peritrophic membrane of the mosquito midgut and cross the midgut epithelium. Once through the epithelium, the ookinete enters the basil lamina, and forms an oocyst.
During the ookinete stage, genetic recombination can occur. This takes place if the ookinete was formed from male and female gametes derived from different populations. This can occur if the human host contained multiple populations of the parasite, or if the mosquito fed from multiple infected individuals within a short time-frame.
Over the period of a 1–3 weeks, the oocyst grows to a size of tens to hundreds of micrometres. During this time, multiple nuclear divisions occur. After oocyst maturation is complete, the oocyst divides to form multiple haploid sporozoites. Immature sporozoites break through the oocyst wall into the haemolymph. The sporozoites then migrate to the salivary glands and complete their differentiation. Once mature, the sporozoites can proceed to infect a human host during a subsequent mosquito bite.
Cell division occurs through a process known as schizogony. This is a type of mitotic division in which multiple rounds of nuclear divisions occur before the cytoplasm segments.
Within a red blood cell, P. falciparum resides inside the parasitophorous vacuole. This is formed during erythrocyte invasion.
The proteins originating in the parasite pass through the membrane of the parasitophorous vacuole, and are transported to the cytoplasm or membrane of the erythrocyte. This transport mechanism is largely unknown.
Plasmodium falciparum, and other members of the apicomplexa phylum, contain an organelle called the apicoplast. The apicoplast is an essential plastid, homologous to a chloroplast, although the apicoplast is not photosynthetic. Evolutionarily, it is thought to have derived through secondary endosymbiosis.
The apicoplast contains a 35-kb genome, which encodes for 30 proteins. Other, nuclear-encoded, proteins are transported into the apicoplast using a specific signal peptide. It is estimated that 551, or roughly 10%, of the predicted nuclear-encoded proteins are targeted to the apicoplast.
As humans do not harbor apicoplasts, this organelle and its constituents are seen as a possible target for antimalarial drugs.
The genome of Plasmodium falciparum (clone 3D7) was fully sequenced in 2002. The parasite has a 23 megabase genome, divided into 14 chromosomes. The genome codes for approximately 5,300 genes. About 60% of the putative proteins have little or no similarity to proteins in other organisms, and thus currently have no functional assignment. It is estimated 52.6% of the genome is a coding region, with 53.9% of the putative genes containing at least one intron.
The P. falciparum genome has an AT content of roughly 80.6%. Within the intron and intergenic regions, this AT composition rises to roughly 90%. The putative exons contain an AT content of 76.3%. The parasite's AT content is very high in comparison to other organisms. For example, the entire genomes of Saccharomyces cerevisiae and Arabidopsis thaliana have AT contents of 62% and 65%, respectively.
The subtelomeric regions of P. falciparum chromosomes show a high degree of conservation within the genome, and contain significant amounts of repeated structure. These conserved regions can be divided into five subtelomeric blocks. The blocks contain tandem repeats in addition to non-repetitive regions.
Many genes involved in antigenic variation are located in the subtelomeric regions of the chromosomes. These are divided into the var, rif, and stevor families. Within the genome, there exist 59 var, 149 rif, and 28 stevor genes, along with multiple pseudogenes and truncations.
A transcriptome analysis has been conducted on the intraerythrocytic development cycle of P. falciparum. Roughly 60% of the genome is transcriptionally active during this portion of the parasite's life cycle. Whereas many genes appear to have stable mRNA levels throughout the cycle, many of the genes are transcriptionally regulated in a continuous cascade.
The transition from early trophozoite to trophozoite to schizont correlates with the ordered induction of genes related to transcription/translation machinery, metabolic synthesis, energy metabolism, DNA replication, protein degradation, plastid functions, merozoite invasion, and motility.
Closely adjacent genes along the chromosome do not exhibit common transcription characteristics. Thus, genes are likely individually regulated along the parasite chromosome.
Conversely, the apicoplast genome is polycistronic and most of its genes are coexpressed during the intraerythrocytic development cycle.
There are 5,268 predicted proteins in Plasmodium falciparum, and roughly 60% share little or no similarity to proteins in other organisms and thus are without functional assignment. Of the predicted proteins, 31% contain at least one transmembrane domain, and 17.3% have a signal peptide or signal anchor.
The parasite has different subsets of its proteome expressed during various stages of its developmental cycle. In one study, of the 2,415 proteins were identified in four stages(sporozoite, merozoite, trophozoite, gametocyte), representing 46% of the theoretical number of proteins. Only 6% of the proteins were found in all of the four stages. Of the proteins found, 51% were annotated as hypothetical proteins.
Merozoites contained high levels of cell recognition and invasion proteins. Trophozoites contained proteins implicated in erythrocyte remodeling and hemoglobin digestion. Gametocytes contained high amounts of gametocyte-specific transcription factors and cell cycle/DNA processing proteins. The gametocytes had low levels of polymorphic surface antigens. Sporozoites contained large amounts of proteins related to invasion, as well as members of the var and rif families.
During the erythrocytic stage of the parasite's life cycle, it uses intracellular hemoglobin as a food source. The protein is broken down into peptides, and the heme group is released and detoxified by biocrystallization in the form of hemozoin.
Genes encoding for the TCA cycle enzymes are present in the genome, but it is unclear whether the TCA cycle is used for oxidation of glycolytic products to be used for energy production, or for metabolite intermediate biosynthesis. It has been hypothesized that the main function of the TCA cycle in P. falciparum is for production of succinyl-CoA, to be used in heme biosynthesis.
Genes for nearly all of the pentose phosphate pathway enzymes have been identified from the genome sequence.
It has been hypothesized that the parasite obtains all, or nearly all, of its amino acids by salvaging from the host or through the degradation of hemoglobin. This is supported by the fact that genomic analysis has found no enzymes necessary for amino acid biosynthesis, except for glycine-serine, cysteine-alanine, aspartate-asparagine, proline-ornithine, and glutamine-glutamate interconversions.
Human immune system evasion
The var genes encode for the P. falciparum erythrocyte membrane protein 1 (PfEMP1) proteins. The genes are found in the subtelomeric regions of the chromosomes. There exist an estimated 59 var genes within the genome.
The proteins encoded by the var genes are ultimately transported to the erythrocyte membrane and cause the infected erythrocytes to adhere to host endothelial receptors. Due to transcriptional switching between var genes, antigenic variation occurs which enables immune evasion by the parasite.
The rif genes encode for repetitive interspersed family (rifin) proteins. The genes are found in the subtelomeric regions of the chromosomes. There exist an estimated 149 rif genes within the genome.
Rifin protein are ultimately transported to the erythrocyte membrane. The function of these proteins is currently unknown.
The stevor genes encode for the sub-telomeric variable open reading frame (stevor) proteins. The genes are found in the subtelomeric regions of the chromosomes. There exist an estimated 28 stevor genes within the genome.
The function of the stevor proteins is currently unknown.
- Wirth, Dyann (3 October 2002). "The parasite genome: Biological revelations". Nature 419 (6906): 495–496. doi:10.1038/419495a.
- "DPDx - Malaria Image Library".
- "Malaria eModule - Transmission".
- "Malaria Site: Anopheles Mosquito".
- "Malaria eModule - Exo-Erythrocytic Stages".
- Bozdech, Zbynek (August 18, 2003). "The Transcriptome of the Intraerythrocytic Developmental Cycle of Plasmodium falciparum". PLoS Biology 1 (1).
- Cowman (24 February 2006). "Invasion of Red Blood Cells by Malaria Parasites". Cell 124: 755–766. doi:10.1016/j.cell.2006.02.006.
- "Malaria eModule - ASEXUAL ERYTHROCYTIC STAGES".
- "Malaria eModule - SYNCHRONICITY".
- "Malaria eModule - GAMETOCYTOGENESIS".
- Billker (March 19, 1998). "Identification of xanthurenic acid as the putative inducer of malaria development in the mosquito". Nature 392: 289–292. doi:10.1038/32667. PMID 9521324.
- Gardner, Malcom (3 October 2002). "Genome sequence of the human malaria parasite Plasmodium falciparum". Nature 419 (6906): 498–511. doi:10.1038/nature01097. PMID 12368864.
- Florens (3 October 2002). "A proteomic view of the Plasmodium falciparum life cycle". Nature 419 (6906): 520–526. doi:10.1038/nature01107.
- Bonday, Z.Q. (2002). "Import of host delta-aminolevulinate dehydratase into the malarial parasite: Identification of a new drug target". Nature Medicine 6 (8): 898–903. doi:10.1038/78659.
- Jewett , Sibley (2003). "Aldolase forms a bridge between cell surface adhesins and the actin cytoskeleton in apicomplexan parasites". Mol Cell 11 (4): 885–94. doi:10.1016/S1097-2765(03)00113-8. PMID 12718875.
- Bergman (2003). "Myosin A tail domain interacting protein (MTIP) localizes to the inner membrane complex of Plasmodium sporozoites". J Cell Sci 116 (1): 39–49. doi:10.1242/jcs.00194.
- Baum (2005). "Invasion by P. falciparum merozoites suggests a hierarchy of molecular interactions". PLoS Pathog 1 (4): e37. doi:10.1371/journal.ppat.0010037.
- Bosch (2007). "The closed MTIP-myosin A-tail complex from the malaria parasite invasion machinery". J Mol Biol 372 (1): 77–88. doi:10.1016/j.jmb.2007.06.016. PMC 2702245. PMID 17628590.
- Bosch (2007). "Aldolase provides an unusual binding site for thrombospondin-related anonymous protein in the invasion machinery of the malaria parasite". Proc Natl Acad Sci USA 104 (17): 7015–20. doi:10.1073/pnas.0605301104. PMC 1855406. PMID 17426153.
- Daher , Soldati-Favre (2009). "Mechanisms controlling glideosome function in apicomplexans". Cur Opin Micro 12 (4): 408–414. doi:10.1016/j.mib.2009.06.008.
- Sibley (2010). "How apicomplexan parasites move in and out of cells". Cur Opin Biotech 21 (5): 592–598. doi:10.1016/j.copbio.2010.05.009.
- Hain and Bosch (2013). "Autophagy in Plasmodium, a multifunctional pathway?". CSBJ 8 (11). doi:10.5936/csbj.201308002.
- Boucher and Bosch (2013). "Development of a multifunctional tool for drug screening against plasmodial protein-protein interactions via surface plasmon resonance. |". J. Mol. Recognit. 26 (10): 496–500. doi:10.1002/jmr.2292. PMID 23996492.
EOL content is automatically assembled from many different content providers. As a result, from time to time you may find pages on EOL that are confusing.
To request an improvement, please leave a comment on the page. Thank you!